bristol-myers squibb - Search News

News

Bristol Myers Cuts Earnings Outlook

Barron's on MSN · 2d

Bristol Myers Beats Earnings Expectations. It’s Still Optimistic About New Schizophrenia Drug.

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs expire in the coming years.

Reuters on MSN · 2d

Bristol Myers tops revenue expectations on strength of older drugs, shares fall

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling brands, but failed to convince investors that newer products could drive future growth and shares fell nearly 5%.

Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion

Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 billion, almost flat year over year. U.S. sales slipped 3% to $8.5 billion,

23h

Bristol-Myers Squibb: Declines Have Gone Too Far

Bristol-Myers Squibb sees stabilizing sales, growth in key drugs, and raised guidance. Click to read more about why BMY is an ...

Fierce Pharma2d

Bristol Myers touts commercial execution, reckons with recent clinical setbacks

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

BioPharma Dive5d

Bain leads $300M investment in startup built on Bristol Myers immune drugs

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

1d

Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields

Bristol-Myers Squibb remains a compelling Buy despite the market's over-reaction to the industry and macro headwinds. Learn ...

2d

Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

1don MSN

Bristol-Myers Squibb (BMY) Gains FDA Nod for TYK2 Inhibitor Sotyktu

Bristol-Myers Squibb Company (NYSE:BMY) ranks among the best medical stocks to buy according to analysts. Bristol-Myers ...

StockStory.org on MSN2d

Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced in Q2 CY2025, but sales were flat year on year at $12.27 ...

3d

Bristol-Myers Squibb shares rise as Q2 results boosted by growth portfolio

Bristol-Myers Squibb reported second-quarter earnings that exceeded analyst expectations, driven by strong performance across ...

4d

How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?

Over the past five years, BMY's one-day stock returns following earnings announcements have been evenly split: ...

3don MSN

Bristol-Myers delivers double beat and raises full-year sales forecast

Bristol-Myers Squibb (BMY) shares rise after beating Q2 forecasts, raising 2025 revenue outlook, and showcasing growth in key ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results